Reviewing Dicerna Pharmaceuticals Inc. (DRNA)’s and G1 Therapeutics Inc. (NASDAQ:GTHX)’s results

As Biotechnology businesses, Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and G1 Therapeutics Inc. (NASDAQ:GTHX), are affected by contrast. This especially applies to their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals Inc. 6.91M 98.84 93.05M -2.23 0.00
G1 Therapeutics Inc. N/A 0.00 78.18M -2.59 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Dicerna Pharmaceuticals Inc. and G1 Therapeutics Inc.

Profitability

Table 2 provides us Dicerna Pharmaceuticals Inc. and G1 Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals Inc. -1,346.60% -90.8% -74.4%
G1 Therapeutics Inc. 0.00% -37.6% -35.4%

Liquidity

The Current Ratio of Dicerna Pharmaceuticals Inc. is 6.3 while its Quick Ratio stands at 6.3. The Current Ratio of rival G1 Therapeutics Inc. is 28.7 and its Quick Ratio is has 28.7. G1 Therapeutics Inc. is better equipped to clear short and long-term obligations than Dicerna Pharmaceuticals Inc.

Analyst Ratings

The table given features the ratings and recommendations for Dicerna Pharmaceuticals Inc. and G1 Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dicerna Pharmaceuticals Inc. 0 0 4 3.00
G1 Therapeutics Inc. 0 0 0 0.00

Dicerna Pharmaceuticals Inc.’s upside potential is 129.57% at a $25 consensus target price.

Insider & Institutional Ownership

The shares of both Dicerna Pharmaceuticals Inc. and G1 Therapeutics Inc. are owned by institutional investors at 88.6% and 83.9% respectively. Insiders owned 0.1% of Dicerna Pharmaceuticals Inc. shares. Competitively, insiders own roughly 0.2% of G1 Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dicerna Pharmaceuticals Inc. -14.76% -14.58% -20.51% 1.03% 66.36% 40.75%
G1 Therapeutics Inc. -13.68% -23.61% -48.84% -19.51% 68.97% 66.33%

For the past year Dicerna Pharmaceuticals Inc. was less bullish than G1 Therapeutics Inc.

Summary

G1 Therapeutics Inc. beats Dicerna Pharmaceuticals Inc. on 6 of the 10 factors.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.